Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 13 March 2017, 22:19 HKT/SGT

Source: Jacobson Pharma Corporation
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong
Strategic Move in Advancing Sales Channel for Wider Distribution of its Proprietary Medicine Brands

HONG KONG, Mar 13, 2017 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, announced today that it will acquire 70% interest in Hong Ning Hong Group (comprising "Hong Ling Hong Limited" and its Hong Kong subsidiary), at a total consideration of HK$56 million. When the acquisition is completed, the Hong Ning Hong Group will become an indirect non-wholly owned subsidiary of Jacobson Pharma.

This is a strategic move undertaken by Jacobson Pharma to advance its sales channel and expand its distribution network, and thereupon strengthens its presence and penetration in the OTC market segment. Currently, the Group's OTC drugs and proprietary Chinese medicines are available in a number of Asian markets including Hong Kong, Macau, Singapore, Malaysia, Indonesia and the PRC.

The Hong Ning Hong Group was established in 1992 and has been actively involved in the retail and wholesale of OTC drugs as well as proprietary Chinese medicines in Hong Kong. It has a well-established commercial infra-structure and customer network that can help Jacobson Pharma reach out to its targeted customers in the southern China region. This retail and wholesale platform has significant bearing upon the Group in enhancing both the market coverage and penetration of its proprietary medicines and will help create a high level of synergies through leveraging of the Group's brand management and distribution resources.

Jacobson Pharma has been building an expandable proprietary medicine platform through strategic acquisitions. Its product portfolio now comprises popular household brands including Po Chai Pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok Oil, Contractubex Scar Gel, Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "This acquisition accelerates the growth momentum of the Group's proprietary medicine business and facilitates our penetration into China. Through the retail and wholesale activities of Hong Ning Hong Group, we will be able to acquire first-hand market intelligence which is valuable for our capitalizing on market opportunities and new product developments. Moving forward, we will continue to focus on advancing our channel sales strategy, aiming for greater penetration into the OTC market segments in Hong Kong and China."

About Jacobson Pharma Corporation

Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012 according to Frost & Sullivan. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Chai Kung Tji Thung San, Contractubex Scar Gel Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet are widely carried in the market. For more details about Jacobson Pharma, please visit the Group's website:

Strategic Financial Relations Limited
Vicky Lee     Tel: (852) 2864 4834  Email:
Angela Ng     Tel: (852) 2864 4855  Email:
Queenie Chan  Tel: (852) 2864 4851  Email:
Fax: (852) 2527 1196

Mar 13, 2017 22:19 HKT/SGT
Source: Jacobson Pharma Corporation

Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Jacobson Pharma Corporation
Dec 20, 2017 23:00 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
Dec 20, 2017 21:58 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
Nov 22, 2017 22:12 HKT/SGT
Jacobson Pharma Announces FY2018 Interim Results
Oct 3, 2017 17:44 HKT/SGT
Jacobson Pharma Issues HK$500M Convertible Notes to Dragons 615 Ltd and HH InRe JP, Ltd.
Sept 6, 2017 11:30 HKT/SGT
Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd.
June 25, 2017 09:20 HKT/SGT
Jacobson Pharma Announces 2017 Annual Results
Jan 18, 2017 19:44 HKT/SGT
Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet; Creating an Expandable Proprietary Medicine Platform
Dec 13, 2016 09:17 HKT/SGT
Jacobson Pharma Announces Acquisition of 100% Interest in Ho Chai Kung Brand
Nov 23, 2016 21:27 HKT/SGT
Jacobson Pharma Announces 2016 Interim Results
Oct 31, 2016 22:00 HKT/SGT
Jacobson Pharma Completes Acquisition of Reputable Generic Drug Manufacturer in Hong Kong
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: